{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:19:10Z","timestamp":1791357550747,"version":"4.3.1"},"reference-count":56,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T00:00:00Z","timestamp":1255478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bipolar Disorders"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:p><jats:bold>Objective:\u2002<\/jats:bold> Asenapine is approved for bipolar disorder and schizophrenia. This was a 3\u2010week, randomized, double\u2010blind, placebo\u2010controlled trial of asenapine for treating acute bipolar mania.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> After a single\u2010blind placebo run\u2010in period, adults (n\u2003=\u2003488) experiencing manic or mixed episodes were randomized to flexible\u2010dose sublingual asenapine (10\u2003mg BID on day 1; 5 or 10\u2003mg BID thereafter; n\u2003=\u2003194), placebo (n\u2003=\u2003104), or oral olanzapine (15\u2003mg BID on day 1; 5\u201320\u2003mg QD thereafter; n\u2003=\u2003191). Primary efficacy, change in Young Mania Rating Scale (YMRS) total score from baseline to day 21, was assessed using analysis of covariance with last observation carried forward [(LOCF); primary analysis]. A mixed model for repeated measures [(MMRM); prespecified secondary analysis] was also used to assess efficacy. Tolerability and safety assessments included adverse events, physical examinations, extrapyramidal symptom ratings, and laboratory values.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Mean daily dosages were asenapine 18.2\u2003mg and olanzapine 15.8\u2003mg. Significantly greater least squares (LS) mean \u00b1 SE changes in YMRS scores were observed on day 2 with asenapine (\u22123.0\u2003\u00b1\u20030.4) and olanzapine (\u22123.4\u2003\u00b1\u20030.4) versus placebo (\u22121.5\u2003\u00b1\u20030.5, both p\u2003&lt;\u20030.01) and were maintained until day 21 (\u221210.8\u2003\u00b1\u20030.8 with asenapine, \u221212.6\u2003\u00b1\u20030.8 with olanzapine; both p\u2003\u2264\u20030.0001 versus placebo, \u22125.5\u2003\u00b1\u20031.1) with LOCF. The results of MMRM analyses were consistent with those of LOCF. Asenapine had a modest impact on weight and metabolic measures.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> These results indicate that asenapine is rapidly acting, efficacious, and well tolerated for patients with bipolar I disorder experiencing an acute manic episode.<\/jats:p>","DOI":"10.1111\/j.1399-5618.2009.00748.x","type":"journal-article","created":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T14:35:27Z","timestamp":1255530927000},"page":"673-686","source":"Crossref","is-referenced-by-count":149,"title":["A 3\u2010week, randomized, placebo\u2010controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states"],"prefix":"10.1111","volume":"11","author":[{"given":"Roger S","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Alphs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Macek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Panagides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.463003.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200321090-00001"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370404900208"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.5.543"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106068395"},{"key":"e_1_2_6_8_2","first-page":"322","article-title":"The cost\u2010effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder","volume":"12","author":"Calvert NW","year":"2006","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.6.559"},{"key":"e_1_2_6_10_2","first-page":"44","article-title":"The economic value of lamotrigine as a mood stabilizer: a U.S. managed care perspective","volume":"17","author":"Simons WR","year":"2004","journal-title":"Manag Care Interface"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0502"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(99)00108-0"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/00048670701392841"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0507"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1205"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0306"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1651"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000169068.34322.70"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106059693"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082944"},{"key":"e_1_2_6_22_2","unstructured":"Saphris\u00ae(asenapine).Full prescribing information Schering\u2010Plough Kenilworth NJ USA 2009."},{"key":"e_1_2_6_23_2","unstructured":"PeetersPAM BockbraderH SpaansEet\u00a0al.Asenapine pharmacokinetics: influence of hepatic and renal impairment. Proceedings of the American Psychiatric Association Orlando FL USA April 3 2008."},{"key":"e_1_2_6_24_2","unstructured":"GerritsMGF DoorstamDP SpaansE De GreefHJMM PeetersPAM.Effect of valproate on the glucuronidation of asenapine. Proceedings of the American Society for Clinical Pharmacology and Therapeutics Orlando FL USA April 3 2008."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(08)70669-2"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1004"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(02)00335-3"},{"key":"e_1_2_6_29_2","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0364-7722(79)90058-4"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.06.021"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199303000-00006"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-12"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_2_6_36_2","first-page":"1172","article-title":"How to examine patients using the abnormal involuntary movement scale","volume":"39","author":"Munetz MR","year":"1988","journal-title":"Hosp Community Psychiatry"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.310"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.267"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.02.006"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0116"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.6.1057"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0401"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"e_1_2_6_45_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group","volume":"156","author":"Tohen M","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0704"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00234.x"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.9.844"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0607"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.1.112"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00248.x"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00154.x"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2002.1r084.x"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370404901009"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370204700809"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.852"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/emj.2003.008870"}],"container-title":["Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-5618.2009.00748.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-5618.2009.00748.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T06:22:26Z","timestamp":1696918946000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-5618.2009.00748.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,14]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1399-5618.2009.00748.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-5618.2009.00748.x","archive":["Portico"],"relation":{},"ISSN":["1398-5647","1399-5618"],"issn-type":[{"value":"1398-5647","type":"print"},{"value":"1399-5618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,14]]}}}